HC Wainwright Predicts Weaker Earnings for Krystal Biotech

Krystal Biotech, Inc. (NASDAQ:KRYS) – HC Wainwright reduced their FY2024 earnings per share estimates for Krystal Biotech in a note issued to investors on Monday, November 4th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of $3.64 for the year, down from their prior estimate of $4.01. HC Wainwright currently has a “Buy” rating and a $221.00 target price on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $2.96 per share. HC Wainwright also issued estimates for Krystal Biotech’s Q4 2024 earnings at $1.81 EPS, FY2025 earnings at $5.57 EPS, FY2027 earnings at $9.34 EPS and FY2028 earnings at $9.76 EPS.

KRYS has been the subject of several other reports. Chardan Capital upped their price objective on shares of Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research note on Monday, August 5th. Evercore ISI upped their price target on Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a research report on Monday, August 12th. Citigroup lifted their price objective on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research report on Tuesday. Cantor Fitzgerald restated an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. Finally, William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a report on Friday, August 30th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $197.00.

Krystal Biotech Stock Up 7.6 %

NASDAQ:KRYS opened at $199.61 on Thursday. The firm has a market capitalization of $5.74 billion, a P/E ratio of 112.77 and a beta of 0.82. The company has a fifty day moving average of $181.29 and a 200 day moving average of $180.58. Krystal Biotech has a 52 week low of $93.95 and a 52 week high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The firm had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. During the same quarter in the previous year, the company posted ($0.67) earnings per share. The business’s revenue was up 879.9% on a year-over-year basis.

Institutional Investors Weigh In On Krystal Biotech

Several institutional investors have recently modified their holdings of the business. Jamison Private Wealth Management Inc. bought a new stake in Krystal Biotech during the second quarter valued at about $28,000. GAMMA Investing LLC lifted its holdings in Krystal Biotech by 160.3% in the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock worth $28,000 after purchasing an additional 93 shares in the last quarter. Key Financial Inc bought a new position in Krystal Biotech in the 2nd quarter worth approximately $28,000. Blue Trust Inc. grew its holdings in Krystal Biotech by 2,328.6% during the 2nd quarter. Blue Trust Inc. now owns 170 shares of the company’s stock valued at $30,000 after buying an additional 163 shares in the last quarter. Finally, Values First Advisors Inc. bought a new stake in shares of Krystal Biotech during the third quarter valued at approximately $53,000. 86.29% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the sale, the insider now owns 1,500,882 shares of the company’s stock, valued at $296,814,424.32. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 14.10% of the stock is owned by corporate insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).